SCHEMBL4767967

SCHEMBL4767967

Cc1cc(C(=O)Nc2ccc3c(c2)CCN(C2CCC2)CC3)n(C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.48
RAB9A P51151 5/20 0.44
NPC1 O15118 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HRH1 P35367 1/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
USP2 O75604 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KDR P35968 2/20 0.43
BACE1 P56817 1/20 0.42
AURKA O14965 1/20 0.42
PDGFRB P09619 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768406 0.87 HRH3 (0.46) HRH3RAB9AHRH1ALDH1A1LMNA
SCHEMBL4768724 0.87 BLM (0.46) HRH3RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4768299 0.85 KMT2A (0.59) HRH3MEN1KMT2AALDH1A1LMNA
SCHEMBL4777073 0.85 POLB (0.52) HRH3RAB9ANPC1HRH1
SCHEMBL4767869 0.83 HRH3 (0.49) HRH3RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4765424 0.82 HRH3 (0.47) HRH3RAB9ANPC1SMN1; SMN2MAPT
Trifluoroacetic Acid SCHEMBL4775304 0.82 SLC2A1 (0.43) HRH3HRH1ALDH1A1LMNABACE1
Trifluoroacetic Acid SCHEMBL4774899 0.81 SLC2A1 (0.43) HRH3RAB9ANPC1SMN1; SMN2MAPT
Trifluoroacetic Acid SCHEMBL4775487 0.81 KMT2A (0.53) MEN1KMT2AALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL4772057 0.80 POLB (0.47) HRH3RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP claimed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US claimed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed
EP-1713778-A1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-10-25 EP disclosed
WO-2005058837-A1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 HRH3 1/4885RAB9A 2307/4885NPC1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.